Apr 19 2025

​New Mexico: $49 Million in Legal Marijuana Sold Across 1.2 Million Transactions in March, $140 Million in Q1 2025​

According to updated data from the New Mexico Regulation and Licensing Department, the state recorded $49.2 million in marijuana sales across 1.2 million transactions in March, bringing the 2025 total to $140 million.

(Photo credit: GETTY Images).

The state recorded $49,283,455.96 in total marijuana sales for the month, including $37,418,519.05 from adult-use sales and $11,864,936.90 from medical marijuana. So far in 2025, sales have reached $139,297,997.96. Since launching its legal market, the state has now brought in $1,645,431,848.10 from 36,685,512 total transactions.

New Mexico legalized recreational marijuana through the Cannabis Regulation Act, signed into law by Governor Michelle Lujan Grisham on April 12, 2021. Legal sales began on April 1, 2022, allowing adults 21 and older to purchase marijuana from licensed retailers. Home cultivation is also allowed, with up to six mature plants per adult and 12 per household.
Continue reading

Apr 19 2025

Texas Psychedelic Research Bill Scheduled for Public Hearing in House Public Health Committee on April 21

A bill mandating a statewide study on the therapeutic use of psychedelics for mental health treatment is set for a public hearing in Texas.

(Photo credit: Getty Images).

House Bill 4014, introduced by State Representative John Bucy (R), is set to be heard by the House Public Health Committee on April 21 at 12:00 p.m. in room E2.030. The bill would require the Department of State Health Services to conduct a comprehensive study into the use of psychedelic therapies for treating post-traumatic stress disorder (PTSD), depression, and other co-occurring conditions.

Under the measure, the research would be conducted in collaboration with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at The University of Texas at Austin. The study would review existing clinical trials and scientific literature, evaluate treatment guidelines, and assess access to current therapies for PTSD and depression. If the substances are approved by the U.S. Food and Drug Administration (FDA), the department would also be tasked with providing recommendations for improving access to psychedelic-assisted therapy.
Continue reading

Apr 18 2025

Clinical Trial: CBD Improves Naming Function in People With Parkinson’s Disease

A randomized, double-blind clinical trial conducted at Buriram Hospital in Thailand found that daily sublingual cannabidiol (CBD) was safe for individuals with Parkinson’s disease and led to improvements in naming ability, an important aspect of cognitive function.

The trial included 60 Parkinson’s disease patients, evenly split between those receiving a CBD-enriched product and those given a placebo. The CBD product delivered approximately 26 mg of CBD and 1.2 mg of THC per day. After 12 weeks, 51 participants remained for analysis.

While the study found no statistically significant differences in the primary outcome—delayed recall on the Montreal Cognitive Assessment (MoCA)—those in the CBD group experienced a small but statistically significant improvement in naming scores. The placebo group, on the other hand, improved in language scores, while the CBD group did not.
Continue reading

Apr 18 2025

Study: Psilocybin-Assisted Therapy Shows Promise for Treating Alcohol and Tobacco Addiction

A new comprehensive review published in the journal Neuroscience & Biobehavioral Reviews finds growing evidence that psilocybin, the psychoactive compound in magic mushrooms, may help treat substance use disorders—especially alcohol and tobacco addiction—when combined with psychotherapy.

The study was conducted by researchers from eight universities across five countries, including the NYU Grossman School of Medicine, Imperial College London, the University of Toronto, and institutions in Australia and the Netherlands. They performed a detailed analyses of 16 published peer-reviewed studies alongside 26 active clinical trials.

Of the studies reviewed, nearly 44% focused on alcohol use disorder, and 31% investigated tobacco use disorder. The remaining studies addressed other addictions such as opioids, cocaine, nicotine, or multiple substances. Most employed open-label or observational designs, with a randomized controlled trial also included.
Continue reading

Apr 18 2025

Nevada Senate Approves Psychedelics Resolution With Overwhelming Bipartisan Support

The Nevada Senate voted 18 to 2 today to approve Senate Joint Resolution 10, a measure urging Congress to reschedule certain psychedelic compounds and expand research into their therapeutic use for treating mental health conditions.

Mescaline (top left), ibogaine (top right), psilocybin mushrooms (bottom left), and DMT (bottom right).

The resolution, backed by a broad coalition of 27 senators and assemblymembers, highlights growing evidence that substances such as psilocybin, MDMA, DMT, ibogaine, mescaline and others could be effective in treating serious conditions like PTSD, treatment-resistant depression, anxiety, substance use disorders and chronic pain.

Citing data from numerous clinical trials and studies at major research institutions including Johns Hopkins, Stanford and Yale, the resolution points to FDA designations of certain psychedelic therapies as “Breakthrough Therapies” and emphasizes their favorable safety profiles when administered in clinical settings.
Continue reading

Apr 18 2025

Study: Cannabis-Based Medicines Improve Quality of Life in Patients With Treatment-Resistant Epilepsy

A new study published by the journal Brain and Behavior, and published online by the National Library of Medicine, found that cannabis-based medicinal products (CBMPs) may improve quality of life for individuals with treatment-resistant epilepsy.

The study, conducted by researchers at Imperial College London and Kings College London, analyzed data from 134 patients enrolled in the UK Medical Cannabis Registry. Researchers tracked patient-reported outcomes over a six-month period, focusing on epilepsy-specific and general health-related quality of life (HRQoL) measures.

Improvements were observed at one, three, and six months across all metrics, including the Quality of Life in Epilepsy-31 (QOLIE-31), Generalized Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Score (SQS), and EQ-5D-5L. Nearly 30% of participants reported a clinically meaningful improvement in epilepsy-specific quality of life by the six-month mark.
Continue reading

Apr 18 2025

Massachusetts Cannabis Control Commission Offers Consumer Education For 4/20

The Massachusetts Cannabis Control Commission is releasing new educational materials ahead of this year’s 4/20 cannabis holiday – the seventh since the first adult-use stores opened in November 2018 – to help consumers aged 21 and older safely navigate the many regulated products sold by licensed retailers.

The Commission’s 4/20 educational campaign includes a new video illustrating how to read labels found on product packaging, and a flyer that describes the effects of the most common cannabis compounds – like THC, CBD, and CBN – available for sale to adult consumers in Massachusetts, according to a Friday press release.

“April 20 remains the most popular day to buy cannabis in Massachusetts, and so we want to help experienced consumers and newcomers gain a new understanding of the range of cannabis products available for sale,” Acting Chair Bruce Stebbins said. “Through these materials, consumers can make more informed choices while shopping at cannabis retailers in the Commonwealth.”
Continue reading

Apr 18 2025

Report: Industrial Hemp Market in North America and Oceania to Surpass $7 Billion by 2030

The industrial hemp market in North America and Oceania is projected to grow rapidly over the next several years, with a new report estimating the market will reach $7.23 billion by 2030.

Hemp plants.

This marks a compound annual growth rate (CAGR) of 20.5% from 2025 through the end of the decade, as demand for sustainable materials and advances in agricultural research drive expansion.

According to the report, the seeds segment dominated the market in 2024 and is expected to maintain its lead, thanks to rising demand for plant-based and sustainable products. Hemp seeds and seed oil are valued for their rich nutritional profile and high content of essential fatty acids, making them popular in food, beverage, and supplement markets. Shives—woody core fragments of the hemp stalk—are gaining traction as well, particularly in animal bedding applications, with a projected CAGR of 17.2%.
Continue reading

Apr 18 2025

Oregon House Approves Legislation to Wipe Out Old Court Fines for Minor Marijuana Offenses

Yesterday, the Oregon House of Representatives voted 41 to 14 to approve a bill that would automatically end certain unpaid court fines and penalties for marijuana-related offenses.

House Bill 3825, sponsored by Representatives Chaichi Chotzen (D) and Tom Andersen (D), targets lingering monetary penalties tied to minor marijuana possession convictions issued by municipal or justice courts. Specifically, the bill states that judgment remedies associated with convictions for possessing less than one ounce of marijuana will expire on the law’s effective date, which is 91 days after the legislative session adjourns.

Under existing law, judgment remedies—such as the collection of fines or other monetary obligations—can persist for years. HB 3825 seeks to remove these lingering penalties for qualifying marijuana offenses, allowing affected individuals to be considered in full compliance with their sentence for the purposes of expungement.
Continue reading

Apr 18 2025

Zippo Announces 4/20 Collection Featuring Limited-Edition Lighter Insert and New Cannabis-Inspired Designs

 Zippo Manufacturing Company, the maker of the iconic Zippo windproof lighter, announced that it’s “celebrating 4/20 with a lineup of lighters and accessories crafted for cannabis enthusiasts.”

Zippo debuts its limited-edition Iridescent Green Single Torch Butane Insert for 4/20, “offering a sleek, high-performance flame with bold cannabis-inspired style.”

At the center of the launch is the new Iridescent Green Single Torch Butane Insert, a limited-edition accessory that brings precision flame, high-performance engineering and a vibrant green finish to the brand’s classic lighter format.

According to Zippo, the insert is designed “to fit seamlessly inside any classic Zippo lighter case, delivering a single torch-style blue flame and refillable butane functionality.” The company says that “paired with one of Zippo’s lighter designs, it offers a sleek, odorless and wind-resistant upgrade for anyone looking to add a pop of personality and performance to their everyday routine.”
Continue reading